@article{9b74eccacccb420c81d9c6fe1996f496,
title = "Immunotherapy toxicities: An SGO clinical practice statement",
keywords = "Cervical cancer, Checkpoint blockade, Endometrial cancer, Immunotherapy, Pembrolizumab, Toxicity",
author = "O'Cearbhaill, {R. E.} and L. Clark and Eskander, {R. N.} and S. Gaillard and J. Moroney and E. Pereira and B. Pothuri",
note = "Funding Information: Dr. Gaillard reports grants from Abbvie, grants from Pfizer, grants from PharmaMar, grants from Iovance, grants from Tesaro, grants from Genentech/Roche, grants from Rigel, grants and personal fees from AstraZeneca, personal fees from Immunogen, personal fees from Sermonix, personal fees from Elevar Therapeutics, all outside the submitted work. In addition, Dr. Gaillard has a patent US 16/341,033 licensed, and a patent PCT/US2019/026669 licensed. Funding Information: Dr. O'Cearbhaill is funded in part by the NIH/NCI Cancer Center Support Grant P30 CA008748 . ",
year = "2022",
month = jul,
doi = "10.1016/j.ygyno.2022.05.003",
language = "English (US)",
volume = "166",
pages = "25--35",
journal = "Gynecologic oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",
}